论文部分内容阅读
目的比较咪唑斯汀缓释片与氯雷他定片治疗过敏性鼻炎的有效性与安全性。方法本研究为多中心、双盲、平行对照研究,107例患者随机分为po咪唑斯汀10mg(n=54)组和po氯雷他定10mg(n=53)组,疗程1~2周。结果咪唑斯汀和氯雷他定均能缓解过敏性鼻炎的症状。经过1周或2周治疗后,喷嚏、流涕、鼻塞、鼻痒等症状的严重性明显降低,下鼻甲水肿明显改善。患者对两药的耐受性是相同的,两药对心肌的复极均无影响。结论本研究表明咪唑斯汀与氯雷他定治疗过敏性鼻炎同样有效和耐受,而且与氯雷他定一样起效迅速。
Objective To compare the efficacy and safety of mizolastine sustained-release tablets and loratadine tablets in the treatment of allergic rhinitis. Methods This multicenter, double-blind, parallel-controlled study of 107 patients was randomly divided into po mizolastine 10mg (n = 54) group and po loratadine 10mg (n = 53) . Results Mizolastine and loratadine can relieve the symptoms of allergic rhinitis. After 1 week or 2 weeks of treatment, sneezing, runny nose, stuffy nose, nasal itching and other symptoms significantly reduced the severity of inferior turbinate edema significantly improved. Patient tolerance to the two drugs is the same, the two drugs have no effect on myocardial repolarization. Conclusions This study shows that mizolastine and loratadine are equally effective and tolerable in the treatment of allergic rhinitis and have the same rapid onset of efficacy as loratadine.